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Diagnostic, Prognostic, and Therapeutic Implications
of Genetic Testing for Hypertrophic Cardiomyopathy
J. Martijn Bos, MD,* Jeffrey A. Towbin, MD,‡ Michael J. Ackerman, MD, PHD*†
Rochester, Minnesota; and Cincinnati, Ohio
Over the last 2 decades, the pathogenic basis for the most common heritable cardiovascular disease, hypertro-
phic cardiomyopathy (HCM), has been investigated extensively. Affecting approximately 1 in 500 individuals,
HCM is the most common cause of sudden death in young athletes. In recent years, genomic medicine has been
moving from the bench to the bedside throughout all medical disciplines including cardiology. Now, genomic
medicine has entered clinical practice as it pertains to the evaluation and management of patients with HCM.
The continuous research and discoveries of new HCM susceptibility genes, the growing amount of data from
genotype-phenotype correlation studies, and the introduction of commercially available genetic tests for
HCM make it essential that the modern-day cardiologist understand the diagnostic, prognostic, and thera-
peutic implications of HCM genetic testing. (J Am Coll Cardiol 2009;54:201–11) © 2009 by the American
College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.02.075D
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cffecting 1 in 500 people, hypertrophic cardiomyopathy
HCM) is a disease marked by phenotypic and genotypic
eterogeneity and is the most prevalent, heritable cardio-
ascular disease. HCM is the most common cause of sudden
ardiac death in young athletes (1). HCM can manifest
egligible to extreme hypertrophy, minimal to extensive
brosis and myocyte disarray on microscopy, absent to
evere left ventricular (LV) outflow tract obstruction, and
istinct septal morphologies such as reverse curve, sigmoi-
al, and apical HCM. The clinical course varies extremely as
ell, ranging from an asymptomatic lifelong course to
yspnea and/or angina refractory to pharmacotherapy to
udden death as the sentinel event. Fully described for the
rst time by Teare (2) in 1958, HCM was regarded as
asymmetrical hypertrophy of the heart in young adults.” It
as since been referred to by an array of names—idiopathic
ypertrophic subaortic stenosis (3), muscular subaortic ste-
osis (4), and hypertrophic obstructive cardiomyopathy
5)—reflecting its clinical heterogeneity and its relatively
ncommon occurrence in daily cardiologic practice.
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dentification of HCM susceptibility genes. Nearly 20
ears ago, the first chromosome locus for familial HCM and
ubsequently mutations involving the MYH7-encoded beta-
yosin heavy chain were elucidated as the pathogenic basis
or HCM (6,7). Since then several hundreds of mutations
cattered among at least 27 putative HCM susceptibility
enes encoding various sarcomeric, calcium-handling, and
itochondrial proteins have been identified (Tables 1 and 2). The
ost common genetically mediated form of HCM is
yofilament (sarcomeric)-HCM with hundreds of disease-
ssociated mutations in 9 genes encoding proteins (myofila-
ents) critical to the cardiac sarcomere. This includes
eta-myosin heavy chain (MYH7) (7), regulatory (MYL2)
nd essential myosin light chains (MYL3) (8), myosin
inding protein C (MYBPC3) (9), cardiac troponin T
TNNT2), alpha-tropomyosin (TPM1) (10), cardiac tropo-
in I (TNNI3) (11), cardiac troponin C (TNNC1) (12), and
ctin (ACTC) (13,14). Complete screening through a large
ohort of patients has not been performed, yet targeted
creening of giant sarcomeric TTN-encoded titin, which
xtends throughout one-half of the sarcomere, has thus far
evealed only 1 mutation (15).
Expanding the scope of proteins involved in the pathogen-
sis of HCM, the spectrum of HCM-associated genes has
oved outside the myofilaments of the sarcomere to encom-
ass additional subgroups that could be classified as ‘Z-disc-
CM’ and ‘calcium-handling HCM’ (Table 1). Due to its
lose proximity to the contractile apparatus of the myofilament,
ts specific structure-function relationship with regard to cyto-
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Genetic Testing in HCM July 14, 2009:201–11architecture, as well as its role in
the stretch-sensor mechanism of
the sarcomere, attention subse-
quently focused on the cardiac
Z-disc. This focus has been fueled
by the fact that HCM and dilated
cardiomyopathy (DCM) are par-
tially allelic disorders, in which
mutations in the same genes—
especially the Z-disc—can be re-
sponsible for both cardiomyo-
pathic phenotypes (16–24). The
first Z-disc mutations associated
with HCM were described in
muscle LIM protein encoded by
CSRP3 (21) and telethonin en-
coded by TCAP (23). Recently,
LDB3-encoded LIM domain
binding 3, ACTN2-encoded alpha
actinin 2, VCL-encoded vinculin/
etavinculin (24–26), and MYOZ2-encoded myozenin-2 (27)
ave been added to that list. In another demonstration of muta-
ions in 1 gene causing multiple diseases, MYPN-encoded myo-
alladin (MYPN) mutations were implicated in the pathogenesis
f DCM, HCM, and restrictive cardiomyopathy via disturbed
yofibrillogenesis, abnormal gene expression, and/or abnormality
n assembly of Z-disc and intercalated disc (E. Purevjav, T.
rimura, S. Augustin, et al., unpublished data, June 2009).
In yet another signal transduction pathway, proteins
nvolved in calcium-induced calcium release and the hy-
Abbreviations
and Acronyms
ACE  angiotensinogen-I
converting enzyme
DCM  dilated
cardiomyopathy
HCM  hypertrophic
cardiomyopathy
LV  left ventricle/
ventricular
LVH  left ventricular
hypertrophy
LVNC  left ventricular
noncompaction
miRNA  micro-ribonucleic
acid
RAAS  renin-angiotensin-
aldosterone system
RNA  ribonucleic acid
Summary of Hypertrophic Cardiomyopathy SusceTable 1 Summary of Hypertrophic Cardiomy
Gene Locus
Myofilament HCM
TTN 2q24.3 Titin
MYH7 14q11.2–q12 Beta
MYH6 14q11.2–q12 Alph
MYL2 12q23–q24.3 Vent
MYL3 3p21.2–p21.3 Vent
MYBPC3 11p11.2 Card
TNNT2 1q32 Card
TNNI3 19p13.4 Card
TPM1 15q22.1 Alph
ACTC 15q14 Alph
TNNC1 3p21.3–p14.3 Card
Z-disc HCM
LBD3 10q22.2–q23.3 LIM b
CSRP3 11p15.1 Musc
TCAP 17q12–q21.1 Telet
VCL 10q22.1–q23 Vincu
ACTN2 1q42–q43 Alph
MYOZ2 4q26–q27 Myoz
Calcium-handling HCM
JPH2 20q12 Junc
PLN 6q22.1 PhosGenes in bold are available as commercial genetic tests.othesis that errors in this process may lead to compensa-
ory hypertrophy have always been of high interest in the
athogenesis of HCM. Mutations have been described in
he promoter and coding region of PLN-encoded phospho-
amban, an important inhibitor of cardiac muscle sarco-
lasmic reticulum Ca(2)-ATPase (28,29). Recently it
as been shown that mutations in JPH2-encoded junc-
ophilin 2 (JPH2), which helps approximate the sarco-
lasmic reticulum calcium release channels and plasmale-
mal L-type calcium channels, may cause HCM (30).
ew insights and approaches to genomics of cardiac
ypertrophy and HCM. Not only in molecular genetics
ut also in other fields of ‘-omics,’ novel pathways under-
ying the pathophysiology of cardiac hypertrophy and HCM
ave been identified using several new techniques to study
arge-scale transcriptional changes (31–33). A transcrip-
omic approach can be performed by using microarray, a
echnique that enables a snapshot view of gene expression,
hich, combined with complex analytic tools, can identify
enes that are differentially regulated or seem to be coregu-
ated, thereby forming a transcriptional network of genes
nd pathways. Microarray chips can hold over tens of
housands of genes and can be utilized to compare expres-
ion levels in certain disease states with healthy control
ubjects.
In 2002, Hwang et al. (34) studied ribonucleic acid
RNA) from heart failure patients with either HCM or
CM and found almost 200 genes to be up-regulated and
1 genes down-regulated in both conditions, as well as
everal genes differentially expressed between the 2 diseases
lity Genesy Susceptibility Genes
Protein Frequency (%)
1
n heavy chain 15–25
in heavy chain 1
regulatory myosin light chain 2
essential myosin light chain 1
osin-binding protein C 15–25
ponin T 5
ponin I 5
myosin 5
ac actin 1
ponin C 1
domain 3 (alias: ZASP) 1–5
protein 1
1
etavinculin 1
in 2 1
1
-2 1
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-myosi
a-myos
ricular
ricular
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July 14, 2009:201–11 Genetic Testing in HCMroviding information on different pathways and genes
nvolved in the pathogenesis. Rajan et al. (35) performed
icroarray analysis on ventricular tissue of 2 previously
eveloped transgenic, 2.5-month-old HCM mice (alpha-
M175 and -TM180) carrying mutations in alpha-
ropomyosin (TPM1). Studying 22,600 genes, 754 differen-
ially expressed genes between transgenic and nontransgenic
ice were detected, of which 266 were differentially regu-
ated between the 2 different mutant hearts showing most
ignificant changes in genes belonging to the ‘secreted/
xtracellular matrix’ (up-regulation) and ‘metabolic en-
ymes’ (down-regulation).
Another emerging field is that of micro-ribonucleic acids
miRNAs) and their role in cardiac development and
hypertrophic) heart disease. These fundamental cellular
egulators were first described by Lee et al. (36) in 1993 and
onsist of approximately 22 noncoding ribonucleic acid
olecules that silence genes through post-transcriptional
egulation. miRNAs play an important role in cardiac
evelopment as well as in orchestrating organogenesis and
arly embryonic patterning processes (37,38). Furthermore,
hese noncoding ribonucleic acid molecules seem to play an
mportant role in cardiac remodeling and the development
f hypertrophy as initially reported by van Rooij et al. (39)
n 2006. Utilizing 2 mouse models of pathological hypertro-
hy, transverse aortic constriction, and calcineurin transgenic
ice, 6 miRNAs were up-regulated, which in vitro were
ufficient to induce hypertrophic growth of cardiomyocytes
39). Furthermore, a transgenic mouse model overexpressing 1
f these miRNAs (miR-195) showed that a single miRNA
ould induce pathological hypertrophy and heart failure (39).
ver the last year, multiple studies have been published with
iRNA expression profiles in different settings, in vivo and in
itro, of cardiac hypertrophy (37,39,40–43). Lastly, polony
HCM PhenocopiesTable 2 HCM Phenocopies
Gene Locus
TAZ Xq28 Tafazzi
DTNA 18q12 Alpha-d
PRKAG2 7q35–q36.36 AMP-ac
LAMP2 Xq24 Lysosom
mem
GAA 17q25.2–q25.3 Alpha-1
GLA Xq22 Alpha-g
AGL 1p21 Amylo-
FXN 9q13 Frataxin
PTPN11 12q24.1 Protein
nonr
RAF1 3p25 V-RAF-1
onco
KRAS 12p12.1 v-Ki-ras
viral
SOS1 2p22-p21 Son of
Genes in bold are available as commercial genetic tests.
AMP  adenosine monophosphate; HCM  hypertrophic cardiomy
lentigines, electrocardiographic conduction abnormalities, ocular hyp
deafness; LVNC  left ventricular noncompaction; WPW  Wolff-Parkultiplex analysis of gene expression (PMAGE) is a technique phat detects messenger RNAs as rare as 1 transcript per 3
ells (44). Using this new technique, early transcriptional
hanges preceding pathological manifestations were identi-
ed in mice with HCM-causing mutations, including low-
bundance messenger RNA encoding signaling molecules
nd transcription factors that participate in the disease
athogenesis (44).
The development and implementation of these new
echniques as well as their applications in research and
linical models of cardiac hypertrophy and HCM will over
he years teach us more about the pathophysiology of
ormal and pathological hypertrophy as well as HCM.
his, in turn, might lead to discovery of novel disease-
ausing genes, involved pathways, and possible novel ther-
peutic targets.
CM genetic testing in clinical practice. Recently,
CM genetic testing has matured from its 2-decade long
esidence in research laboratories into the realm of clinically
vailable, diagnostic testing for physicians evaluating and
reating patients with this disease (Harvard Partners, Cor-
elagen, PGxHealth, and GeneDX). These companies now
ffer testing for the 8 most common myofilament associated
enes; additional genes offered by some are the genes
nvolved in the glycogen storage diseases or the recently
iscovered HCM-associated gene troponin-C encoded by
NNC1. The HCM susceptibility genes available for com-
ercial genetic testing are highlighted in bold in Tables 1
nd 2.
Although some of the new HCM susceptibility genes
ay surpass the prevalence of mutations found in some of
he myofilament proteins, MYBPC3 and MYH7 remain by
ar the most common HCM-associated genes, with an
stimated prevalence of 15% to 25% for both genes. Among
he 9 HCM-associated, myofilament-encoding genes, the
rotein Syndrome
) Barth syndrome/LVNC
revin Barth syndrome/LVNC
protein kinase WPW/HCM
ociated
protein 2
Danon’s syndrome/WPW
osidase deficiency Pompe’s disease
sidase A Fabry’s disease
cosidase Forbes disease
Friedrich’s ataxia
ne phosphatase,
r type 11, SHP-2
Noonan’s syndrome,
LEOPARD syndrome
e leukemia viral
omolog 1
Noonan’s syndrome,
LEOPARD syndrome
en rat sarcoma
ene homolog
Noonan’s syndrome
ess homolog 1 Noonan’s syndrome
LEOPARD  mnemonic for syndrome with clinical characteristics of
ism, pulmonary hypertension, abnormal genitalia, retarded growth,
hite syndrome.P
n (G4.5
ystrob
tivated
e-ass
brane
,4-gluc
alacto
1,6-glu
tyrosi
ecepto
murin
gene h
2 Kirst
oncog
sevenl
opathy;revalence of myofilament HCM has ranged from 35% to
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Genetic Testing in HCM July 14, 2009:201–115% in several different international cohorts of unrelated
atients who met the clinically accepted definition of HCM
45,46).
chocardiography-guided genetic testing. While several
henotype-genotype relationships have emerged to enrich
he yield of genetic testing, most of these patient profiles
ave not been particularly clinically informative. Recently,
he possibility of echocardiography-guided genetic testing
as been explored (47). Noting a predominance of sigmoi-
al HCM among the elderly, Lever et al. (48) suggested
ver 2 decades ago that there was a strong age dependence
ith the various septal morphologies of HCM, where septal
ontour was classified as reverse curve, sigmoidal, apical, and
eutral contour HCM (Fig. 1). In the early 1990s, Solomon
t al. (49) observed that patients with mutations in the
eta-myosin heavy chain (MYH7-HCM) generally had
eversed curvature septal contours (reverse curve HCM).
Subsequently, a large genotype-phenotype analysis corre-
ating the septal morphology with the underlying genotype
as conducted. After extensive analysis of the echocardio-
rams of nearly 400 unrelated patients, sigmoidal HCM
47% of cohort) and reverse curve HCM (35% of cohort)
epresented the 2 most prevalent anatomical subtypes of
CM (Fig. 1). In this study, the yield of genetic testing for
yofilament HCM (8 genes) was 80% in reverse curve
CM, but only 10% in patients with sigmoidal HCM, and
eptal contour was the strongest predictor of a positive
CM genetic test, regardless of age (odds ratio: 21,
 0.0001) (47). These observations may facilitate
chocardiography-guided genetic testing by enabling in-
ormed genetic counseling about the pre-test probability of a
ositive genetic test based upon the patient’s expressed
natomical phenotype (Fig. 2).
ole of HCM genetic testing for both index cases and
elatives. Although in the future there may be some
rognostic relevance presently and therapeutic relevance to
he HCM genetic test in the index cases that already
~ 10% Myofilament 
Gene +
Sigmoidal     
HCM              
40 - 50%
Reverse curve 
HCM          
30 - 40%
~ 80% Myofilamen
Gene +
Figure 1 Septal Morphologies in HCM
Shown are the most common septal morphologies in hypertrophic cardiomyopathy
cohort of patients with HCM is shown along the top while the yield of genetic testlinically manifest the disease, the principal role for index
ase genetic testing is diagnostic. It can, however, as we will
how later on, be of significant importance to the approach
nd screening of relatives.
Figure 2 provides a flow chart for clinicians, in which the
pathways are described when an index case (HCM
roband) is identified. It must be recognized that, before a
iagnosis of HCM in the proband is made, a full history,
xamination, including extensive family history, should be
erformed. This way, clues can be picked up to expose other
auses of unexplained left ventricular hypertrophy (LVH)—
ortic stenosis, hypertension, or the presence of a phenocopy—
s being responsible for the patient’s symptoms. For example,
igns of ventricular pre-excitation might point to a PRKAG2-
ediated glycogen storage disease or an inheritance pattern
hat strictly affects male patients might suggest LAMP2-
ediated disease. If the phenotype is HCM, echocardiography
ay inform genetic counseling by providing an a priori
robability for a positive genetic test and advice on how to
roceed with further evaluation and family screening (left arm
f algorithm). If genetic testing of the major genes remains
egative, the presence of a phenocopy with pure cardiac
nvolvement should be considered.
As it stands now, genetic testing of the index case has the
otential of providing the diagnostic gold standard for
is/her offspring, siblings, and parents and more distant
elatives. A positive genetic test would then enable system-
tic scrutiny of the index case’s relatives to separate the
haves’ from the ‘have nots’ (positive vs. negative test). In
ther words, the genetic testing of the index case risk
tratifies the family enabling 2 very different courses to be
harted: 1) close surveillance of the genotype-positive,
re-clinical individual; and 2) casual observation or dis-
issal of the genotype-negative/phenotype-negative relative
nd his/her future progeny.
In general, and irrespective of genetic testing, once a
iagnosis of HCM has been rendered, all first-degree
Apical                  
HCM                 
~ 10% 
30% Myofilament
Gene +
Neutral           
HCM             
~ 10%
~ 40% Myofilament
Gene +
). The distribution of septal morphologies among a large
each morphological subgroup is shown along the bottom of the figure.    
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July 14, 2009:201–11 Genetic Testing in HCMelatives and probably ‘athletic’ second-degree relatives to
he index case should be screened by an electrocardio-
ram and echocardiogram. Annual screenings are recom-
ended for adolescents and young adults (age 12 to 25
ears) and athletes, and thereafter every 3 to 5 years. As
ntimated previously, if an HCM-causing mutation is
stablished for the index case, first-degree relatives
hould have confirmatory genetic testing performed for
hat particular HCM-causing mutation. Depending on
he established familial versus sporadic pattern, confir-
atory genetic testing should proceed in concentric
ircles of relatedness.
For example, if the index case’s mutation is present in
is/her father, then the paternal grandparents and pater-
al aunts/uncles should be tested. The index case’s
rst-degree cousins may or may not need genetic testing
epending on the results of the testing among the aunts
nd uncles and so forth. If a phenotype-negative family
ember tests negative for the index case’s mutation, then
uture cardiologic evaluations for that relative and his/her
rogeny may not be necessary. However, a decision to
ease surveillance for HCM in a relative hinges critically
n the certainty of the identified gene/mutation and its
Genetics-Based Screening
A priori chance of positive genetic 
test based on septal contour
Reverse curve HCM     80%                                                     
Neutral HCM 40%         
Apical HCM 30%    
Sigmoidal HCM 10%
Confirm mutation in 
first degree  relatives
Clinic HC
Genetic testing                 
performed ?
Mutation identified?
Mutation identified?
HCM
Perform
echoca
YES
YES
YES
NO
NO
NO
Figure 2 Genetic- and Echocardiographic-Based Screening in H
Flow chart showing a possible decision tree to follow in genetic- and echocardiogra
ability for a positive genetic test result based on the echocardiographic scored sep
testing.ausative link as well as the complete absence of any sraditional evidence used to clinically diagnose HCM
i.e., asymptomatic and normal echocardiogram).
Aside from the role of genetic testing described in the
receding text, there is still concern among patients and
ractitioners on social and economic aspects of knowing
nes genetic make-up. For example, genetic testing may
r may not be covered by an individual’s health insurance
lan. Some payors view HCM genetic testing as a bona
de clinical test while others view it as an ‘investigational’
ne. Secondly, if genetic testing is performed, a patient
ight feel anxiety about the potential clinical dangers of
osting an HCM-predisposing mutation. Also, there
ight be fears that the presence of this information in
ne’s medical records might influence health insurance
remiums and employment opportunities, although this
ast issue has been addressed recently by former President
ush’s signing of the Genetic Information Nondiscrim-
nation Act (GINA) into law. This is an important step
o provide protection against genetic discrimination.
esides discussing the differential impact in terms of
ollow-up for a genotype-positive relative compared with
genotype-negative relative as described earlier, these
mportant issues should also comprise the genetic coun-
Echocardiography-Based 
Screening 
Screen first degree relatives and 
athletic second degree relatives
roband
Repeat 
echocardiogram 
every 5 years
(annual for young adults 
and athletes)
No further screening
Consider phenocopies
nfirmed
al clinical and 
raphic exam
Positive 
echocardiogram ?
NOYES
sed screening in hypertrophic cardiomyopathy (HCM). Noted is the a priori prob-
ntour, as well as the steps to follow if a patient chooses not to pursue genetic     
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Genetic Testing in HCM July 14, 2009:201–11ovel imaging techniques for early detection of HCM
isease gene expression. With growing knowledge on
enetics and other pathogenetic pathways in HCM, it
ould be very helpful if parameters could be found that
uggest pre-clinical, pre-hypertrophic expression of the
enetic substrate. Tissue Doppler echocardiography studies
n transgenic rabbit models of HCM (50–52) and in
umans have shown reduced myocardial Doppler velocities
n genotype-positive subjects without LVH (50,53–55).
agueh et al. provided the first evidence in 2001 demon-
trating that myocardial contraction and relaxation velocities
s detected by tissue Doppler are reduced in familial,
utation-positive HCM (54). In 2002, Ho et al. (55)
howed that abnormalities of diastolic function as assessed
y Doppler tissue imaging precede development of LVH in
atients with MYH7 mutations where a combination of Ea
elocity and ejection fraction was highly predictive of
ffected phenotype in patients without hypertrophy (55).
ardiac magnetic resonance imaging is also showing poten-
ial to become an important tool in the diagnosis of HCM
s it has capacity to acquire images with tissue contrast and
order definition that is often superior to echocardiography
56–59). In 2006, Germans et al. (60) performed cardiac
agnetic resonance imaging on 16 mutation-positive HCM
atients and detected pre-hypertrophic crypts in the infero-
eptal LV wall, possibly representing early pathological
lterations stemming from the pathogenic substrate.
rognostic Implications of HCM Genetic Testing
rom the early beginnings of the genomic era and since the
escription of the first HCM-causing mutation, investiga-
ors have attempted to correlate genotypes to particular
linical phenotypic expressions. Stemming from earlier ped-
gree studies, specific missense mutations were associated
ith a markedly unfavorable prognosis whereas others had
n uneventful natural history. These observations resulted in
pecific mutations being designated as either ‘malignant’
utations or ‘benign’ mutations (61–68). The first study of
ts kind was published by Watkins et al. (61) in 1992 in
hich they described mutations in MYH7 found in 12 of 25
amilies with HCM. They concluded that the MYH7-
403Q mutation was associated with a significantly shorter
ife expectancy, and could therefore be considered a ‘malig-
ant’ mutation. In contrast, a noncharge change mutation
V606M) was associated with nearly normal survival and
herefore was considered ‘benign’ (61). In 2003, Woo et al.
69) analyzed mutations in functional domains in 15 (of 70)
YH7-positive probands and concluded that there may be
rognostically informative domains.
Initial reports on the clinical expression from the most
ommon subtype of HCM—MYBPC-HCM—seem to
how a slower, but progressive clinical disease course, with
ater onset and milder disease characteristics (68,70,71).
nvestigators in the Netherlands and South Africa have
iscovered founder mutations in MYBPC3 with mild phe- notypic expression that are present in at least 30% of their
ases (72). Similarly, certain genotype-phenotype correla-
ions were attributed to TNNT2 (troponin T)-HCM. Far
ess common than MYBPC-HCM or MYH7-HCM,
NNT2-HCM (affecting 5% of patients) was associated
ith less severe LV wall thickness, but a higher incidence
f premature sudden cardiac death (64,73,74). Overall,
hese TNNT2-HCM patients who suddenly died had
ess hypertrophy and less fibrosis, but more myocyte
isarray, which may have provided the substrate for
alignant arrhythmias (74).
Overall, these observations have been gleaned from small
ohorts involving larger families with penetrant disease
xpression whereas genotype-phenotype studies involving
arge cohorts of unrelated patients have indicated that great
aution must be exercised with assigning particular prog-
ostic significance to any particular mutation (75–77). In 1
uch cohort, only 2% hosted 1 of those formally annotated
benign’ mutations and, moreover, these particular hosts
isplayed a severe clinical phenotype with all 5 patients
equiring surgical myectomy, 3 of the 5 having a family
istory of sudden cardiac death, and 1 adolescent requiring
n orthotopic heart transplant (77). In contrast, 3 patients
osting a so-called ‘malignant’ mutation displayed a here-
ofore mild phenotype (75). Furthermore, these studies have
emonstrated that the 2 most common forms of genetically
ediated MYH7-HCM and MYBPC3-HCM—are phe-
otypically indistinguishable (78).
More recently, in one of the first studies of its kind for
CM, a longitudinal study in a large cohort of unrelated
talian patients with HCM has shown an increased risk of
ardiovascular death, nonfatal stroke, or progression to New
ork Heart Association functional class III/IV among
atients with a positive HCM genetic test involving any of
he myofilament genes compared with those patients with a
egative genetic test (25% vs. 7%, respectively; p  0.002)
Fig. 3A); multivariate analysis showed myofilament-
ositive HCM (i.e., a positive genetic test) to be the
trongest predictor of an adverse outcome (hazard ratio:
.27 [95% confidence interval: 1.43 to 12.48]; p  0.008)
79). Furthermore, patients with myofilament genotype-
ositive HCM had greater probability of developing severe
V systolic dysfunction (p 0.021) (Fig. 3B) and restrictive
V filling (p  0.018) (Fig. 3C).
Lastly, it has been observed that patients with multiple
utations (i.e., compound or double heterozygotes), de-
ected in about 3% to 5% of genotype-positive patients, have
more severe phenotype and increased incidence of sudden
eath (78,80,81), suggesting a gene-dosage effect might
ontribute to disease severity. Interestingly, in the majority
f cases of compound heterozygosity, one of the mutations
sually involves MYBPC3 (78). In their longitudinal study,
livotto et al. (79) observed a similar trend showing that
atients with double mutations (of which 1 was usually
YBPC3) had greater disease severity than myofilament-egative patients or patients with a single MYBPC3, thick
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Fig. 3D).
In summary, although clinical prognostication must be
endered with great caution for specific gene domains or
pecific genetic mutations, a positive HCM genetic test in
eneral portends a greater likelihood for disease progression,
articularly as it pertains to systolic and diastolic dysfunc-
ion and propensity to develop symptoms. As such, clinical
enetic testing may thereby aid in the prognostication of a
atient’s disease outcome.
nterpretation of rare variants and phenocopies. One
roup of patients that pose an intriguing challenge for
linicians is that of patients with seemingly unexplained
VH that mimics the HCM phenotype. These diseases
re usually referred to as phenocopies, and the most
mportant ones are listed in Table 2. Phenocopies or
are variants pose a tough dilemma for the clinician. If
he phenotype does not look like typical HCM and
ther symptoms like ventricular pre-excitation or
uscle weakness are present, the presence of an under-
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(MYH7), myosin binding protein C (MYBPC3), and regulatory and essential myosinying multisystem disease should be considered, and Tdditional clinical testing should be performed. On the
ther hand, if myofilament genetic testing does not
eveal an HCM-associated mutation, testing for muta-
ions in the metabolic genes can reveal that the LVH is
he primary presentation of a multisystem disease
rocess.
A different cardiomyopathy and phenocopy that can
resent itself with seemingly unexplained hypertrophy is
hat of left ventricular noncompaction (LVNC)—a primary
ardiomyopathy characterized by a severely thickened
-layered myocardium, numerous prominent trabeculations,
nd deep intertrabecular recesses (82,83). Although genet-
cally still largely unexplained, mutations in the TAZ-
ncoded tafazzin (G4.5)—also associated with Barth
yndrome—DTNA-encoded alpha-dystrobrevin and LDB3
ave been associated in the pathogenesis of LVNC (84–
6). Recently, Klaassen et al. (87) systematically analyzed a
ohort of 63 unrelated patients with LVNC for mutations in
myofilament-encoding genes, identifying 9 distinct het-
rozygous mutations in 11 patients in MYH7, ACTC, and
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pathies of HCM, DCM, and LVNC.
Some diseases presenting chiefly with cardiac hypertro-
hy turn out to have clearly distinct underlying pathophys-
ologies. In 2001, 2 independent groups discovered
RKAG2 mutations being involved in families with cardiac
ypertrophy and ventricular pre-excitation, conduction ab-
ormalities, and signs of Wolff-Parkinson-White syndrome
88–90). In 2005, Arad et al. (91) also described mutations
n lysosome-associated membrane protein-2 encoded by
AMP2 and PRKAG2 and found that underlying glycogen
torage diseases mimicked the clinical phenotype of HCM.
ang et al. (92) showed that LAMP2 mutations may
ccount for a significant portion of patients diagnosed with
ediatric or juvenile onset HCM, especially when skeletal
yopathy and/or Wolff-Parkinson-White syndrome are
resent.
ole of modifiers in HCM. The role of modifiers of the
CM phenotype, either by the presence of common polymor-
hisms or founder mutations, has become the subject of recent
nvestigations. The most important subgroup of polymor-
hisms, studied to date, involve the major components of the
enin-angiotensin-aldosterone system (RAAS). Polymor-
hisms in the RAAS pathway (angiotensinogen-I converting
nzyme [ACE], angiotensin receptor 1 [AGTR1], chymase 1
CMA], angiotensin I [AGT], and cytochrome P450,
olypeptide 2 [CYP11B2]: DD-ACE, CC-AGTR1, AA-
MA, T174M- and M235T-AGT, and CC-CYP11B2)
ppear to influence the HCM phenotype, in particular the
everity of LVH (93,94). Among patients with the DD-
CE genotype, there was greater LVH than among those
ith an ID or II genotype (95). Furthermore, a combined
pro-LVH’ profile of 5 RAAS genes was associated with a
igher degree of LVH in one particular, founder
YPBC3-HCM pedigree (93) and in a large cohort of
yofilament-positive patients (94).
In 2008, sex hormone polymorphisms were shown to
odify the HCM phenotype (96). Fewer CAG-nucleotide
epeats in AR-encoded androgen receptor were associated
ith thicker myocardial walls in male subjects (p  0.008),
nd male carriers of the A allele in the promoter of
SR1-encoded estrogen receptor 1 (SNP rs6915267) exhib-
ted an 11% decrease in LV wall thickness (p  0.047)
ompared with GG-homozygote male subjects (96). HCM
odifier polymorphisms like these could contribute to the
linical differences observed between men and women with
CM (97,98). The release of the complete human genome
equence and the enormity of variation in individuals show
growing role for modifier genes and the search for effect by
enome-wide studies. In 2007, Daw et al. (99) performed
he first study of this kind for HCM and they identified
ultiple loci with suggestive linkage. Effect sizes on LV
ass on this cohort of 100 patients ranged from 8 g shift
rom 1 locus for the common allele to 90 g shift for another
ocus’ uncommon allele. rherapeutic Implications of HCM Genetic Testing
harmacogenomics. Currently, there is no available ther-
py specifically designed to target specific HCM-causing
ene mutations or particular HCM genotypes. Further, no
herapies have been shown to reverse the hypertrophic
rocess in humans. One of the first studies of its kind was
erformed in transgenic MYH7-R403Q mice models (des-
gnated MHC403/). In a randomized trial, MHC403/
ice treated with diltiazem, an L-type calcium inhibitor,
howed significant improvement as compared with mice
reated with placebo in terms of cardiac systolic function as
easured by increased end-diastolic and -systolic volumes,
ecreased dP/dTmax values, and end-systolic elastance
100). Furthermore, diltiazem-treated mice showed signif-
cantly less hypertrophy at 30 and 39 weeks than age-
atched MHC403/ untreated mice as well as less fibrosis
nd myocyte disarray on microscopy (100). Recently, Wes-
ermann et al. (101) showed in a different transgenic mouse
odel (TNNT2-I79N) that diltiazem improved diastolic
unction and prevented diastolic heart failure and sudden
ardiac death compared with that seen in untreated mice.
As previously discussed, RAAS polymorphisms modify
he phenotype of HCM, particularly MYBPC3-HCM
93,94), and there is now growing evidence that ACE
nhibitors, especially combined with low doses of aldoste-
one receptor blockers, may attenuate the progression of
ypertrophy and fibrosis (102–106). In early mouse models
f transgenic cardiac troponin T (cTnT-Q92) that exhibit
yocyte disarray and fibrosis, a randomized, blinded trial
omparing losartan (an angiotensin-II blocker) or placebo
emonstrated that losartan significantly reversed fibrosis
nd expression of collagen 1 (I) and transforming growth
actor-beta-1 in the transgenic mice (107). In a similar study
nvolving the same transgenic mice, losartan produced a
0% reduction in myocyte disarray compared with that seen
n mice treated with placebo as well as complete normal-
zation of the collagen volume fraction (108).
Lastly, another group of drugs, statins, may favorably
odify the phenotype of HCM. A study involving 24
ransgenic mice harboring the MYH7-R403Q mutation
howed a regression of hypertrophy and fibrosis, improved
ardiac function, and reduced extracellular signal-regulated
inases 1 and 2 activity after treatment with simvastatin
ompared to 12 nontransgenic mice (109). Similar results
ere observed in transgenic rabbits with this mutation that
ere treated with atorvastatin (110). However, a small,
andomized controlled pilot study failed to show an effect on
umans with HCM (111).
Therefore, one can envision that, with increasing knowl-
dge of the patient’s pathogenic substrate and polymor-
hism profile, specific therapies may someday emerge. In
ther cases, for example, the proper and prompt recognition
f an HCM phenocopy such as cardiac Fabry’s disease can
acilitate gene-specific pharmacotherapy such as enzyme-
eplacement therapy. Albeit rare, such clinical sleuthing can
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July 14, 2009:201–11 Genetic Testing in HCMnable early treatment and prevent the progression of the
isease. Recently, human trials such as the DELIGHT
DiltiazEm Long-term In Genotype-positive Hypertrophic
ardiomyopathy as preclinical Treatment) trial have begun
nd are examining whether calcium-channel inhibitors like
iltiazem can prevent the development of hypertrophy
mong patients with genotype-positive, LVH-negative
CM (112).
onclusions
enomic medicine, as it pertains to HCM, has moved from
he bench to the bedside, but caution is needed to interpret
nd manage the genetic portfolio of a patient. Although
ome prognostic forecasts may be gleaned from the HCM
enetic test, therapeutic decisions regarding use of a defi-
rillator should not be dictated by the genetic test result.
nstead, knowledge of the genetic background in subjects
ith HCM has significant diagnostic implications, and
chocardiography may help guide genetic testing by provid-
ng anticipatory guidance and a pre-test probability of a
ositive genetic test result. Clearly, knowledge of disease-
ausing mutations in an index case enables rapid genetic
esting and diagnosis of potentially at-risk relatives thereby
roviding improved and informed follow-up and treatment
ecisions for such family members. The information gained
n these subjects can define risk status and, in those subjects
ith negative genetic screening, less close follow-up and
esting over time and psychological freedom.
Increasingly, clinical care in HCM and other genetic-
ased disorders includes the wise use and wiser interpreta-
ion of genetic tests. Therefore, understanding the genetic
nderpinnings of disease and the risk placed on these
ubjects will be imperative for all patients and their families.
he 21st century clinician must be cognizant of the state-
f-the-art of translational genetics in order to best care for
heir patients and families, as well as to help to define new
linical guidelines over the next decade.
eprint requests and correspondence: Dr. Michael J. Ackerman,
ayo Clinic Windland Smith Rice Sudden Death Genomics
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